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and inflammatory indicators, the high-sensitivity C-reactive peptide (hs-CRP) and glycoprotein acetyls (GlycA), in sporadic
and C9orf72 repeat expansion-associated frontotemporal lobar degeneration (FTLD) patients. The C9orf72 hexanucleotide
repeat expansion is the most frequent genetic etiology underlying FTLD. The concentrations of different lipid measures in
the sera of 67 FTLD patients (15 C9orf72 repeat expansion carriers), including GlycA, were analyzed by nuclear magnetic
resonance spectroscopy. To verify the state of systemic inflammation, hs-CRP was also quantified from patient sera. We
found that the total serum HDL concentration was decreased in C9orf72 repeat expansion carriers when compared to non-
carriers. Moreover, decreased concentrations of HDL particles of different sizes and subclass were consistently observed.
No differences were detected in the very low- and low-density lipoprotein subclasses between the C9orf72 repeat expansion
carriers and non-carriers. Furthermore, hs-CRP and GlycA levels did not differ between the C9orf72 repeat expansion carriers
and non-carriers. In conclusion, the HDL-related changes were linked with C9orf72 repeat expansion associated FTLD but
were not seen to associate with systemic inflammation. The underlying reason for the HDL changes remains unclear.
Keywords: C9orf72 protein, cholesterol, frontotemporal dementia, frontotemporal lobar degeneration, inflammation,
lipoproteins
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is the
second most common cause of dementing diseases in
working-age people and accounts for approximately
10% of all progressive dementias [1]. FTLD is clin-
ically divided into two main subcategories, namely
behavioral variant frontotemporal dementia (bvFTD)
[2] and primary progressive aphasias (PPAs) [3].
PPAs are further divided into the following subcate-
gories: nonfluent variant primary progressive aphasia
(nfvPPA) and semantic variant primary progressive
aphasia (svPPA). In addition, the logopenic variant
of primary progressive aphasia (lvPPA) is clinically
considered a subtype of PPA, but is neuropatho-
logically associated with Alzheimer’s disease (AD)
[3].
FTLD presents autosomal dominant inheritance
in up to 50% of patients [4, 5]. The most common
genetic etiology underlying FTLD is the hexanu-
cleotide repeat expansion (GGGGCC) on the short
arm of chromosome 9 open reading frame 72
(C9orf72) [6, 7]. This repeat expansion accounts
for approximately 25% of familial FTLD cases in
Europe and the USA [8]. Besides FTLD, the C9orf72
repeat expansion also causes up to 40% of familial
amyotrophic lateral sclerosis (ALS) cases in these
populations [8]. Investigations in induced pluripo-
tent stem cell-derived neurons from C9orf72 repeat
expansion carriers and different animal models have
suggested that both toxic gain-of-function and loss-
of-function mechanisms underlie C9orf72 repeat
expansion-associated FTLD and ALS [9]. Transcrip-
tion and aberrant repeat-associated non-ATG (RAN)
translation of the expanded C9orf72 hexanucleotide
repeat in both sense and antisense directions have
been shown to lead to the formation and accumu-
lation of expanded repeat-containing RNA foci and
dipeptide-repeat proteins (DPRs) and result in neuro-
toxicity and neurodegeneration. In addition, several
studies have shown that C9orf72 repeat expansion
carriers display an approximately 50% decrease in the
levels of normalC9orf72RNA and protein, indicating
haploinsufficiency as another potential contributor to
disease pathogenesis [9].
Dysfunction in brain lipid homeostasis is sug-
gested to be a risk factor for different neurode-
generative disorders [10, 11]. Altered blood lipid
metabolism is known to associate with cardiovascular
diseases, well-known risk factors for neurodegen-
erative diseases, but also with neurodegenerative
diseases themselves, even though it is presently
unclear if the blood and brain lipid levels corre-
late with each other. Lowered serum high-density
lipoprotein (HDL) cholesterol has been indicated to
be linked to AD [12, 13]. In addition, a decreased
HDL concentration is related to systemic inflamma-
tion [14]. Recent studiesC9orf72knockout mice have
shown drastic systemic inflammation and autoim-
mune disease-like phenotypes. These examinations
together with human studies suggest a potential
role for inflammation in C9orf72 repeat expansion-
associated disease pathogenesis [15–17]. So far only
a few studies have provided insight into the lipid
metabolism in FTLD patients and these studies have
not contained analyses of the genetic background
of the patients [18, 19]. However, the examination
of lipid and cholesterol changes in ALS, a close
pathological analogue to C9orf72 repeat expansion-
associated FTLD, has been more extensive [20–30].
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Dyslipidemia in ALS has also been acknowledged
[21, 29, 30].
Here, our aim was to examine potential alterations
in the serum lipoprotein levels in FTLD patients car-
rying or not the C9orf72 repeat expansion. To our
knowledge, these are the first reported findings that
compare lipoprotein alterations in C9orf72 repeat
expansion carriers to non-carriers.
MATERIALS AND METHODS
Ethical considerations
The study was performed according to the princi-
ples of the Declaration of Helsinki. Written informed
consent was obtained from the participants. The study
protocol was approved by the Research Ethics Com-
mittee of the Northern Savo Hospital District.
Patients
A cohort comprising a total of 67 patients with
FTLD, diagnosed between the years 1996–2017 at
the memory outpatient clinics of Kuopio University
Hospital, was utilized in this study (Table 1). An
experienced neurologist, specialized in cognitive and
dementing disorders, examined all of the patients.
The patients with bvFTD were diagnosed according
to the latest diagnostic criteria by Rascovsky and col-
leagues [2], and patients with PPAs were diagnosed
according to the Gorno-Tempini diagnostic criteria
[3]. A retrospective review based on these same cri-
teria was used for patients who had been originally
diagnosed before the Rascovsky or Gorno-Tempini
criteria were published. All patients with bvFTD,
nfvPPA, or svPPA fulfilled the criteria with either a
probable or a definite diagnosis. Patients with FTLD-
MND had at least a probable diagnosis of bvFTD,
nfvPPA, or svPPA and the clinical manifestation of
motoneuron disease (MND). None of the patients in
our cohort were diagnosed with lvPPA. The serum
samples were collected at the time of diagnosis. Col-
lected samples were aliquoted and frozen (–80◦C) for
future analyses.
Patients with FTLD were further divided into two
subgroups based on their C9orf72 repeat expansion
status: C9orf72 repeat expansion carriers (N = 15)
and C9orf72 repeat expansion non-carriers (N = 36).
Within the clinical subgroups, 14 bvFTD and one
nfvPPA patient carried the C9orf72 repeat expansion.
None of the FTLD-MND or svPPA patients car-
ried the C9orf72 repeat expansion. Genotyping data
of the C9orf72 repeat expansion was not available
for 23.9% (16/67) FTLD patients (13 bvFTD, one
nfvPPA, and one FTLD-MND). Demographic infor-
mation of the study patients is presented in Table 1.
Genetic analyses
The C9orf72 repeat expansion was analyzed using
the repeat-primed polymerase chain reaction assay
[6]. One patient with the C9orf72 expansion carried
an intermediate expansion (28 repeats) and the rest
had the full expansion (>40 repeats). The patients
classified as C9orf72 repeat expansion non-carriers
had less than five repeats. Other genes associated with
FTLD were not analyzed as mutations in these genes
have previously been observed to be extremely rare
in the Finnish population [31, 32].
The apolipoprotein E (APOE) alleles were geno-
typed from extracted genomic DNA with polymerase
chain reaction using TaqMan genotyping assays
(rs429358 and rs7412 polymorphisms, Applied
Biosystems, Foster City, CA, USA) and allelic dis-
crimination (ABI 7500 platform) [33]. The QIAamp
DNA blood mini extraction kit (QIAGEN) was used
to extract genomic DNA from blood.
Table 1
Demographic data and prevalence of the C9orf72 repeat expansion and APOE 4 alleles among diagnosed FTLD patients
bvFTD PPA (nfv + sv) FTLD-MND Total
Cases 49 12 6 67
Sex, f/m 30/19 (61/39%) 7/5 (58/32%) 4/2 (67/33%) 41/26 (61.2/38.8%)
Mean age at diagnosis, y 65.0 69.8 61.8 65.6
C9orf72 carriers/non-carriers 14/21 (40/60%∗) 1/10 (1/10%∗) 0/5 (0/100%∗) 15/36 (29/61%∗)
APOE 4 carriers/non-carriers 15/22 (40.5/ 59.5%∗) 2/8 (20/80%∗) 0/3 (0/100%∗) 17/33 (34/66%∗)
C9orf72 repeat C9orf72 repeat
expansion carriers expansion non-carriers
APOE 4 carriers/non-carriers 3/9 (25/75%∗) 9/14 (39.1/60.9%∗)
∗Ratio of genotyped cases. APOE 4, Apolipoprotein E 4; bvFTD, behavioral variant frontotemporal dementia; C9orf72, Chromosome 9
open reading frame 72; FTDL-MND, Frontotemporal lobar degeneration – motoneuron disease; PPA (nfv + sv), Primary progressive aphasia
(non-fluent variant + semantic variant).
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Lipoprotein analysis
The concentrations for lipoprotein particles, phos-
pholipids, free cholesterol, cholesterol esters, and
triglycerides in the sera for each lipoprotein size and
density were quantified using a nuclear magnetic res-
onance spectroscopy platform [34, 35]. The value for
total lipids in each lipoprotein subclass is calculated
by summing phospholipids, total cholesterol, and
triglycerides. The concentration for total cholesterol
is the sum of free cholesterol and cholesterol esters.
This platform has been used in multiple genetic
and epidemiological setups [36–39]. Lipoprotein data
was missing from one C9orf72 repeat expansion car-
rier and from one non-carrier (both diagnosed with
bvFTD). This same method was used to quantify
glycoprotein acetyls (mainly a1-acid glycoprotein)
(GlycA) from the patient sera. Circulating GlycA
are a prospective and novel biomarker for systemic
inflammation [40].
High sensitivity C-reactive protein
To analyze the state of inflammation in the study
cohort, high sensitivity C-reactive protein (hs-CRP)
was quantified from patient serum with Cobas 8000
(Hitachi High Technology Co, Tokyo, Japan), using
a high sensitive assay for CRP (Latex CRPHS, cat#
04628918 190, Cobas c systems, Roche Diagnostics
GmbH, Mannheim, Germany).
Statistics
An independent two sample t-test was used to test
the significance of differences between the C9orf72
repeat expansion carriers and non-carriers. Hs-CRP
median levels were compared with independent sam-
ples Mann-Whitney U-test.
The normality of distributions was tested by cal-
culating the skewness of data and comparing it to
the skewness value after logarithmic transformation.
Abnormal distribution of a variable was corrected
using logarithmic transformation if the absolute dif-
ference in skewness between logarithmic and native
data was greater than one. The threshold for statistical
significance was p < 0.05.
Statistical analysis was conducted using SPSS
(v23 and v25, IBM Analytics, Armonk, NY, USA).
Figure 1 was generated with R/Rstudio (v3.4.1,
Boston, MA, USA) and ggplot2 third-party R pack-
age (v2.2.1).
RESULTS
We found that the concentration of total HDL
cholesterol in the sera of C9orf72 repeat expansion
carriers was lower when compared to non-carriers
(p = 0.030) (Fig. 1A). Interestingly, there were no dif-
ferences in the serum concentrations of total LDL and
VLDL cholesterol between the C9orf72 carriers and
non-carriers (Fig. 1B, C).
Fig. 1. Differences in the concentrations of serum total cholesterol in HDL (A), LDL (B), and VLDL (C) between C9orf72 repeat expansion
carriers and non-carriers. Total serum cholesterol concentrations in HDL are significantly lower in the repeat expansion carriers when
compared to non-carriers. ∗statistically significant difference, p = 0.030; C9orf72, Chromosome 9 open reading frame 72; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
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Similar findings were observed when the sub-
classes of HDL, LDL, and VLDLs of different
particle sizes were analyzed. The concentration of
total cholesterols in very large HDLs was lower
in the C9orf72 repeat expansion carriers when
compared to non-carriers (p = 0.004). Moreover,
the concentrations of phospholipids (p = 0.010) and
free cholesterol (p = 0.007) as well as total lipids
(p = 0.047) in very large HDLs were also lower. Par-
ticle concentration, and concentrations of cholesterol
esters and triglycerides in very large HDLs did not
differ between the C9orf72 repeat expansion carri-
ers and non-carriers. In addition, differences in the
concentrations of subclasses in large HDLs were sim-
ilar to those in the very large HDL subclasses. The
C9orf72 repeat expansion carriers showed lower con-
centrations of total lipids (p = 0.046), phospholipids
(p = 0.041), free cholesterol (p = 0.046), cholesterol
esters (p = 0.031), and large HDL particles (p = 0.033)
compared to non-carriers. However, the concentra-
tions of total cholesterol and triglycerides in large
HDLs were not altered between the C9orf72 repeat
expansion carriers and non-carriers. In the medium
and small HDL subclasses, only the concentration
of free cholesterol in small HDLs was lower in
the C9orf72 repeat expansion carriers compared to
non-carriers (p = 0.037) (Table 2). Concentrations of
LDL subclasses were similar between the C9orf72
repeat expansion carriers and non-carriers. Likewise,
there were no differences in the VLDL subclasses
between the C9orf72 repeat expansion carriers and
non-carriers. The ratio of free cholesterol and choles-
terol esters in very large HDLs were lower in the
C9orf72 repeat expansion carriers (p = 0.010). There
were no other clear differences in this ratio in any
other HDL subclass or in any VLDL or LDL sub-
classes.
The mean diameter of HDL particles was smaller
in patients carrying the C9orf72 repeat expansion
in comparison to non-carriers (p = 0.035). The mean
Table 2
Differences in particle concentration, total lipids, phospholipids, total cholesterol, cholesterol esters, free cholesterol, and triglycerides in
very large, large, medium, and small high-density lipoproteins between carriers and non-carriers of the C9orf72 repeat expansion
HDL particle size HDL subclass Mean. C9orf72 Mean. C9orf72 p
carriers, mmol/l non-carriers, mmol/l
Very large Particle concentration 3.56e-04 5.28e-04 0.055
Total lipids 0.36 0.54 0.047
Phospholipids 0.14 0.23 0.010
Total cholesterol 0.20 0.29 0.004
Cholesterol esters 0.16 0.21 0.073
Free cholesterol 0.049 0.081 0.007
Triglycerides 0.020 0.023 0.406
Large Particle concentration 1.01e-03 1.42e-03 0.033
Total lipids 0.64 0.89 0.046
Phospholipids 0.30 0.43 0.041
Total cholesterol 0.30 0.43 0.052
Cholesterol esters 0.23 0.32 0.031
Free cholesterol 0.068 0.10 0.046
Triglycerides 0.034 0.041 0.357
Medium Particle concentration 1.81e-03 2.08E-03 0.112
Total lipids 0.77 0.89 0.106
Phospholipids 0.37 0.42 0.108
Total cholesterol 0.37 0.44 0.094
Cholesterol esters 0.29 0.34 0.100
Free cholesterol 0.077 0.095 0.091
Triglycerides 0.036 0.033 0.359
Small Particle concentration 4.69e-03 4.90e-03 0.374
Total lipids 1.04 1.09 0.333
Phospholipids 0.57 0.60 0.376
Total cholesterol 0.43 0.45 0.374
Cholesterol esters 0.32 0.33 0.731
Free cholesterol 0.10 0.12 0.037
Triglycerides 0.047 0.046 0.735
Total cholesterol in HDL 1.3 1.6 0.030
HDL particle diameter 9.9 nm 10.1 nm 0.035
C9orf72, Chromosome 9 open reading frame 72; HDL, high-density lipoprotein. The p-values are presented as native values and are not
subjected to multiple test.
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diameters of VLDL and LDL particles were simi-
lar between the C9orf72 repeat expansion carriers
and non-carriers. Moreover, the concentrations of
phosphatidylcholine and conjugated linoleic acid
were lower in cases carrying the C9orf72 repeat
expansion compared to non-carriers (p = 0.023 and
p = 0.040, respectively). We observed that the con-
centration of triglycerides in small and medium HDL
particles was higher in carriers of two APOE 4
alleles when compared to patients with only one
or no APOE 4 alleles. The APOE 4 genotype
did not affect the concentrations of HDLs in any
other subclass. In addition, we saw that serum HDL
concentrations were consistently lower in men in
nearly every subclass. Furthermore, serum triglyc-
erides in large and small LDL were also lower in
men.
The median hs-CRP concentration in the C9orf72
repeat expansion carriers was 0.60 pg/ml. There was
no difference between the median hs-CRP concen-
trations between C9orf72 repeat expansion carriers
and non-carriers (median hs-CRP in non-carriers was
0.65 pg/ml). The non-carriers showed slightly higher
mean value, but this was due to one bvFTD patient
with hs-CRP concentration of 36.40 pg/ml. In addi-
tion, there were three non-carriers whose hs-CRP
concentrations were under the quantification range
of the assay (0.15 pg/ml). These values were set
to zero. The hs-CRP levels did not correlate with
HDL or LDL concentrations in any lipoprotein sub-
class in carriers and non-carriers combined, but were
observed to negatively correlate with extremely large,
very large, and large VLDLs in multiple subclasses.
We also observed a non-significant trend of slightly
depressed GlycA in FTLD patients with the C9orf72
repeat expansion when compared to those without
(p = 0.064). The mean concentration of GlycA in the
C9orf72 repeat expansion carriers was 1.49 mmol/l
and 1.62 mmol/l in non-carriers.
DISCUSSION
We found here thatC9orf72 repeat expansion carri-
ers show lower concentrations of HDL category lipids
as compared to non-carriers. This alteration in serum
lipids appears to be specific for HDL as no changes
were observed in the concentrations of VLDL or LDL
between these groups. To our knowledge, this is the
first study reporting blood lipoprotein alterations in
C9orf72 repeat expansion associated FTLD patients.
Dyslipidemia has been suggested to associate with
brain atrophy and is thought to occur in neurodegen-
erative diseases, i.e., AD, but not much information is
available on lipid alterations in FTLD. Growing data
suggest that a low concentration of serum HDL may
be associated with an increased risk of certain neu-
rodegenerative diseases. For instance, a lowered HDL
serum cholesterol has been described to associate
with AD [12, 13]. However, contradictory evidence
has also been presented, linking an increased risk of
AD and cholesterol esters relative to total lipids in
large HDL [41].
Our results are in line with previous findings
related to lipoprotein changes in FTLD [18, 19,
42]. It has been previously reported that bvFTD
patients have a lower blood HDL cholesterol con-
centration when compared to AD patients [18]. The
same study also reported an increased total choles-
terol/HDL ratio in bvFTD patients as compared to
a healthy control group. In addition blood triglyc-
erides were elevated in both bvFTD and SD patients
compared to a control group [18]. In a more recent
study, the same group reported increased triglycerides
and a total cholesterol/HDL ratio, and a lowered
HDL cholesterol concentration in ALS and FTD
patients when compared to controls [43]. Further-
more, a recent lipidomics analysis from plasma
showed alterations in different lipid species in bvFTD
as compared to AD patients or controls and suggested
hypertriglyceridemia and hypoalphalipoproteinemia
in bvFTD [19]. Several studies also associate the
incidence and risk of ALS to changes in LDL cat-
egory cholesterols and lipids [20, 21, 23, 27, 29].
The information regarding the involvement of HDL in
ALS is inconclusive. None of these studies, however,
have contained genetic analyses to allow compar-
isons between C9orf72 repeat expansion carriers and
non-carriers. In the study by Wuolikainen et al., the
C9orf72 repeat expansions were confirmed for eleven
ALS patients, but the cholesterol variables were not
examined on the basis of the repeat expansion carrier
status [22].
Chronic inflammation has also been reported to
decrease serum HDL levels [14]. However, the
mechanism by which inflammation may alter lipid
metabolism is not fully understood. As HDL has been
shown to possess anti-inflammatory and antioxidant
properties and is a central transporter of cholesterol
from the tissues to the liver, inflammation might com-
promise this reverse transporter function and thus
promote cholesterol accumulation and exacerbate
inflammatory responses, creating a vicious cycle (see,
e.g., the review by Feingold and Grunfeld in 2016
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[44]). Recently, a plausible association of inflamma-
tory disturbances and FTLD has been proposed. First,
an increased prevalence of autoimmune diseases has
been reported in FTLD patients compared to con-
trols [45–47] and second, FTLD seems to be inversely
linked to cancer [48], which may suggest alterations
in the immune system or responses. Interestingly, the
contribution of autoimmune mechanisms and genetic
variation in loci associated with the immune sys-
tem in FTLD were also suggested in recent studies
[15, 49–51]. In line with these patient-derived data,
C9orf72 repeat expansion has been linked to distur-
bances in the immune system [52], e.g., in mouse
models with loss of function of the C9orf72 gene,
which indicate a severe autoimmune phenotype, high
mortality rate, and increased levels of proinflamma-
tory cytokines and signs of neuroinflammation [16,
17, 52, 53]. On the other hand, a remarkable amount
of FTLD patients display dietary changes [2], which
may partly be related to changes in serum lipid con-
centrations. The C9orf72 repeat expansion associated
FTLD patients have been reported to exhibit less
alterations in eating habits than repeat expansion
non-carriers. In particular the acquired preference
for sweet foods was lower in C9orf72 carriers [54].
As we did not detect alterations in lipid particles
other than HDL, we suggest that eating habits do
not underlie the decreased serum HDL levels in our
study.
Connections between HDLs and inflammation are
not possible to evaluate with our findings. Based on
the hs-CRP and GlycA levels there were no differ-
ences in relation to the C9orf72 repeat expansion
in the FTLD patients. This could, at least partly be
due to the low sample size, but could also reflect
the mechanistic complexity underlying the HDL-
related changes and chronic inflammation. It is also
well known that certain common autoimmune disor-
ders, e.g., rheumatoid arthritis, may not necessarily
increase CRP levels. Furthermore, there are no previ-
ous reports regarding hs-CRP or GlycA in FTLD or
their correlations with the C9orf72 repeat expansion.
Lunette and colleagues connected ALS progression
with hs-CRP [55], but also inconclusive results have
been presented [56]. In the latter study, Nagel et al.
did not see an association between hs-CRP levels and
the risk of ALS. Currently, GlycA has been associ-
ated with systemic inflammation [40, 57] but has not
been as extensively studied in the context of neu-
rodegeneration. A study by Tynkkynen et al. assessed
inflammation in AD and incident dementia by quan-
tifying GlycA but reported only weak associations
[41]. Further research is warranted to better elucidate
these apparently complex associations.
Of the tested cofounding factors, sex significantly
affected the concentrations of lipoprotein variables in
the sera. Men showed lower concentrations of multi-
ple HDL category lipids when compared to women.
However, the prevalence of the APOE 4 allele was
only affecting these HDL levels in two subclasses.
Considering the similarity in sex distributions among
C9orf72 repeat expansion carriers and non-carriers,
we do not suspect that the reported changes in HDL
category lipids between C9orf72 repeat expansion
carriers and non-carriers are due to sex-related dif-
ferences in HDL or lipoprotein metabolism.
Strengths and weaknesses
The strengths of this study include utilization of
a clinically and genetically well-characterized FTLD
patient cohort with a large number of C9orf72 repeat
expansion carriers. However, even though the pro-
portion of C9orf72 expansion carriers in the cohort
is high, the size of the total cohort is limited. Thus,
larger sample sets are needed to confirm the results
obtained in the study. Lipoprotein quantification pro-
vides absolute concentrations, instead of relying
on relative concentrations or signal intensities. The
serum metabolomics platform is thoroughly validated
and used extensively. Another limiting factor is the
fact that the provided p-values were not subjected to
multiple testing. After applying multiple correction,
the p-values depicted non-significant findings, due to
the small sample size. However, a clearly discern-
able trend is obvious and warrants further research to
thoroughly validate the presented association.
Conclusions
We conclude that total serum HDL cholesterol
was lower in FTLD patients with the C9orf72 repeat
expansion. This was consistent in several subclasses
of very large and large HDLs. There were no signif-
icant differences in the concentrations of VLDL or
LDL cholesterol subclasses between C9orf72 repeat
expansion carriers and non-carriers. We did not find
an association between these lipoprotein changes and
quantifiable markers of systemic inflammation, hs-
CRP or GlycA. Thus, the background behind the
presented HDL changes remains unclear and needs
further investigations.
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